Therapy Areas: Inflammatory Diseases
Ananda Pharma receives TGA Acknowledgement for Phase 1 clinical trial
28 April 2025 - UK-based biopharmaceutical company Ananda Pharma plc (AQSE: ANA) ( OTCQB: ANANF) announced on Monday that its Phase I clinical trial for MRX1 has been acknowledged by Australia's ...
argenx receives positive CHMP opinion for VYVGART subcutaneous injection in CIDP treatment
28 April 2025 - Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Formosa Pharmaceuticals and Saval agree licensing deal for clobetasol propionate ophthalmic suspension
28 April 2025 - Taiwan-based Formosa Pharmaceuticals (TW:6838) announced on Friday that the company has entered into an exclusive licensing agreement with Laboratorios Saval, a Chilean pharmaceutical ...
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
24 April 2025 - China-based LakeShore Biopharma Co Ltd (Nasdaq:LSB) announced on Wednesday that it has held the 2025 CSO (Contract Sales Organisation) Annual Meeting and the launch meeting of YSJA rab...
SynAct Pharma secures US patent allowance for resomelagon combination therapy in rheumatoid arthritis
23 April 2025 - Clinical stage biotechnology company SynAct Pharma AB (STO:SYNACT) announced on Wednesday that it has received a Notice of Allowance from the United States Patent and Trademark Office ...
NS Pharma's NS-229 granted US FDA Orphan Drug Designation for treatment of eosinophilic granulomatosis with polyangiitis
22 April 2025 - NS Pharma Inc, a subsidiary of Japan-based Nippon Shinyaku Co Ltd (TYO:4516), announced on Monday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ...